Reserpine Interactions

Use with carbidopa and levodopa is not recommended due to dopamine-depleting effects that may counteract the therapeutic benefit.

Source: NLP:carbidopa and levodopa

Should not be used concomitantly. Must wait at least 20 days after stopping reserpine before starting tetrabenazine to avoid overdosage and major CNS depletion of serotonin and norepinephrine.

Source: NLP:tetrabenazine

Additive effect may cause marked bradycardia or hypotension presenting as vertigo, syncope, or orthostatic changes in blood pressure.

Source: NLP:acebutolol hydrochloride

Additive effect may cause hypotension and marked bradycardia, potentially producing vertigo, syncope, or postural hypotension.

Source: NLP:atenolol

Catecholamine depletor may cause severe hypotension and marked bradycardia with vertigo, syncope, or postural hypotension.

Source: NLP:atenolol and chlorthalidone

Catecholamine-depleting drug that may produce excessive reduction of sympathetic activity when combined with bisoprolol fumarate; close monitoring required.

Source: NLP:bisoprolol fumarate

Catecholamine-depleting drug that with bisoprolol's beta-adrenergic blocking action may produce excessive reduction of sympathetic activity. Close monitoring required.

Source: NLP:bisoprolol fumarate and hydrochlorothiazide

Catecholamine-depleting drug may produce additive effects causing hypotension and/or marked bradycardia, with risk of vertigo, syncope, or postural hypotension.

Source: NLP:brimonidine tartrate and timolol maleate

Possible additive effects producing hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension. Close observation recommended.

Source: NLP:carteolol hydrochloride

Hypotensive agent that may increase risk of hypotension and/or severe bradycardia when combined with carvedilol.

Source: NLP:carvedilol

Catecholamine-depleting agent that may increase risk of hypotension and severe bradycardia when combined with carvedilol.

Source: NLP:carvedilol phosphate

Catecholamine-depleting drug with additive effects; may produce hypotension and/or marked bradycardia, leading to vertigo, syncope, or postural hypotension.

Source: NLP:dorzolamide hydrochloride timolol maleate

Catecholamine-depleting drug with additive effect; may cause hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Source: NLP:metoprolol tartrate

Catecholamine-depleting drug that may have additive effect with metoprolol, increasing risk of hypotension or bradycardia.

Source: NLP:metoprolol tartrate and hydrochlorothiazide

Additive effect with nadolol; monitor closely for hypotension and/or excessive bradycardia (vertigo, syncope, postural hypotension).

Source: NLP:nadolol

Catecholamine-depleting drug; concomitant use may produce excessive reduction of sympathetic activity. Closely monitor patients.

Source: NLP:nebivolol

Catecholamine-depleting drug may produce excessive reduction of sympathetic activity when combined with nebivolol's β-blocking action.

Source: NLP:nebivolol hydrochloride

Centrally-acting sympatholytic agent that increases the pressor effect of phenylephrine hydrochloride.

Source: NLP:phenylephrine hci

Centrally-acting sympatholytic agent that increases the pressor effect of phenylephrine hydrochloride.

Source: NLP:phenylephrine hydrochloride

Additive hypotensive and bradycardic effects; may produce vertigo, syncope, or postural hypotension. Close observation required.

Source: NLP:pindolol

Catecholamine-depleting effect may cause excessive reduction of sympathetic activity resulting in hypotension, bradycardia, vertigo, syncope, or orthostatic hypotension.

Source: NLP:propranolol hydrochloride

Catecholamine-depleting agent; may produce excessive reduction of resting sympathetic nervous tone, causing hypotension and/or marked bradycardia.

Source: NLP:sotalol hydrochloride

Additive effects with beta-blocker may produce hypotension and/or marked bradycardia, leading to vertigo, syncope, or postural hypotension.

Source: NLP:timolol

Catecholamine-depleting drug with potential additive effects producing hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

Source: NLP:timolol hemihydrate

Close observation recommended when timolol is administered with reserpine due to possible additive effects and production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

Source: NLP:timolol maleate

Close observation recommended due to possible additive effects and production of hypotension and/or marked bradycardia, which may result in vertigo, syncope, or postural hypotension.

Source: NLP:timolol maleate ophthalmic gel forming solution

Gastrointestinal acidifying agent that lowers amphetamine absorption and blood levels.

Source: NLP:amphetamine sulfate

Acidifying agent that lowers blood levels and efficacy of amphetamines. Dose adjustment may be needed based on clinical response.

Source: NLP:dextroamphetamine saccharate, amphetamine aspartate, dextroamphetamine sulfate and amphetamine sulfate

Gastrointestinal acidifying agent that lowers amphetamine absorption and blood levels.

Source: NLP:dextroamphetamine sulfate

Antagonizes pressor effect of ephedrine. Carefully monitor blood pressure.

Source: NLP:ephedrine sulfate

May decrease phenytoin serum levels; dose adjustment may be required.

Source: NLP:fosphenytoin sodium

May lead to either potentiation or weakening of glimepiride's glucose-lowering effect.

Source: NLP:glimepiride

May lead to either potentiation or weakening of glucose-lowering effect; may mask hypoglycemia signs.

Source: NLP:glipizide

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring required.

Source: NLP:insulin aspart

May blunt signs and symptoms of hypoglycemia. Increased glucose monitoring may be required.

Source: NLP:insulin aspart-szjj

May blunt signs and symptoms of hypoglycemia. Increased glucose monitoring may be required.

Source: NLP:insulin degludec

May blunt signs and symptoms of hypoglycemia; increased glucose monitoring may be required.

Source: NLP:insulin glargine

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Source: NLP:insulin glulisine

May blunt signs and symptoms of hypoglycemia; increased glucose monitoring required.

Source: NLP:insulin human

May blunt signs and symptoms of hypoglycemia; increased glucose monitoring required.

Source: NLP:insulin lispro

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Source: NLP:insulin lispro-aabc

Catecholamine-depleting drug with additive effect. May cause hypotension, marked bradycardia, vertigo, syncope, or postural hypotension.

Source: NLP:metoprolol

Catecholamine-depleting drug may have additive effect with metoprolol, causing hypotension or marked bradycardia with vertigo, syncope, or postural hypotension.

Source: NLP:metoprolol succinate

Catecholamine-depleting drug may have additive effect with metoprolol, increasing risk of hypotension or marked bradycardia.

Source: NLP:metoprolol succinate er tablets

May blunt signs and symptoms of hypoglycemia. Increased frequency of glucose monitoring may be required.

Source: NLP:nateglinide

Administration with nortriptyline has been shown to produce a "stimulating" effect in some depressed patients. Close supervision and careful dosage adjustment are required.

Source: NLP:nortriptyline hydrochloride

Phenoxybenzamine blocks hypothermia production by reserpine.

Source: NLP:phenoxybenzamine hydrochloride

May decrease phenytoin serum levels; monitoring of phenytoin levels recommended.

Source: NLP:extended phenytoin sodium